Please login to the form below

Not currently logged in
Email:
Password:

Aptalis

This page shows the latest Aptalis news and features for those working in and with pharma, biotech and healthcare.

HIV prevention pill heads July CHMP recommendations

HIV prevention pill heads July CHMP recommendations

Other positive recommendations were given for Aptalis' Truberzi (eluxadoline) as a treatment for irritable bowel syndrome with diarrhoea, along with two biosimilar versions of Sanofi's clot-busting drug Lovenox (enoxaparin) -

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during February 2014 Pharma deals during February 2014

    The announcement came just after Forest completed its acquisition of Aptalis last month for $3bn and this month sold a number of products to Hospira's Australian subsidiary Mayne Pharma for

  • Pharma deals during January 2014 Pharma deals during January 2014

    Almost right to the end of the month, the big headline deal was that of Forest with its planned takeover of Aptalis. ... Aptalis itself was only formed in 2011 following the acquisition of Eurand by the Montreal based Axcan Pharma.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    4, 295. Aptalis/ Forest. Company acquisition. Acquiring sales turnover of $688m. 2, 900.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics